Michael Wagner

This inventor holds 38 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 23 EPO patents, primarily in GLP-1 Agonists. Top assignees: Sanofi, Sanofi-A Ventis Deutschland Gmbh, Sanofi-Aventis. Active years: 2007-2025.

USPTO Granted Patents = 38 (Patent Applications = 11)

% Patents Active = 47.4

CIPO Patents = 2 (Patent Applications = 13)

EPO Patents = 23 (Patent Applications = 33)

Average Co-Inventor Count = 6.2

ph-index = 6

Forward Citations = 120(Granted Patents)

Location History:

Alsbach, DE (2007 - 2011)
Kriftel, DE (2018)
Frankfurt-am-Main, DE (2010 - 2022)

Company Filing History:

Sanofi-A Ventis Deutschland Gmbh

Thyssenkrupp Nucera Ag & Co. Kgaa

patents

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

GLP-1 Agonists

Dual Agonists

Peptidic Compounds

Exendin-4 Derivatives

Pharmaceutical Innovations

Fatty Liver Treatment

Receptor Agonists

Chelating Moiety

Protease Inhibitors

Macrocyclic Urea

Factor Xa Inhibitors

Heterocycles

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12195862 - Use of a textile, zero-gap electrolytic cell and production method therefor (2025-01-14),

2. 11352405 - GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis (2022-06-07),

3. 11141489 - Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid (2021-10-12),

4. 11046743 - Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes (2021-06-29),

5. 10806797 - Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate (2020-10-20),

6. 10792367 - Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid (2020-10-06),

7. 10758592 - Exendin-4 derivatives as dual GLP1/glucagon agonists (2020-09-01),

8. 10538567 - Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists (2020-01-21),

9. 10519211 - Compounds as peptidic GLP1/glucagon/GIP receptor agonists (2019-12-31),

10. 10253079 - Functionalized Exendin-4 derivatives (2019-04-09),

11. 9982029 - Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists (2018-05-29),

12. 9932381 - Exendin-4 derivatives as selective glucagon receptor agonists (2018-04-03),

13. 9834527 - Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals (2017-12-05),

14. 9789165 - Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists (2017-10-17),

15. 9775904 - Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists (2017-10-03),

Title: The Innovative Journey of Michael Wagner

Introduction: Michael Wagner, a visionary inventor hailing from Frankfurt am Main, DE, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Michael Wagner's latest patents include a cutting-edge software application for optimizing energy consumption in smart homes and a revolutionary medical device for non-invasive glucose monitoring.

Career Highlights: With over two decades of experience in the tech industry, Michael Wagner has a proven track record of turning innovative ideas into reality. He has held key positions in leading research institutions and tech companies, where he spearheaded projects that have shaped the future of various industries.

Collaborations: Throughout his career, Michael Wagner has collaborated with top engineers, scientists, and designers to bring his inventions to life. His ability to work seamlessly in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion: Michael Wagner's passion for innovation and his relentless drive to push the boundaries of technology make him a true pioneer in the field of inventions. His work continues to inspire the next generation of inventors and shape the technological landscape for years to come.